Business
Sharp Therapeutics Appoints Co-Founder Of National Gaucher Foundation And Clinical Researcher Robin Ely, M.D., To Advisory Board
PITTSBURGH and TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Sharp Therapeutics Corp. ("Sharp" or the "Company") (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule therapeutics for genetic diseases, announced today the appointment of Robin Ely, M.D., the Clinical Director and co-founder of the National Gaucher Foundation (NGF), to its Advisory Board. Dr. Ely co-founded NGF in 1984 after her son was diagnosed with Gaucher disease. Dr. Ely played a pivotal role in facilit
About this update from Sharp Corporation
[{"type":"image","alt":"Sharp Therapeutics","displaySize":"","headline":null,"caption":"Sharp Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":228,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/342a57148ee79fe7b674371672b8875f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1t_9mbQY1JR1VeRToyOEcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/342a57148ee79fe7b674371672b8875f","width":228,"height":92}},"lazy":false},{"type":"text","content":"PITTSBURGH and TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Sharp Therapeutics Corp. ("Sharp" or the "Company") (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule therapeutics for genetic diseases, announced today the appointment of Robin Ely, M.D., the Clinical Director and co-founder of the National Gaucher Foundation (NGF), to its Advisory Board.","length":398,"tagName":"p"},{"type":"text","content":"Dr. Ely co-founded NGF in 1984 after her son was diagnosed with Gaucher disease. Dr. Ely played a pivotal role in facilitating the U.S. FDA studies and approval of Ceredase, the first enzyme replacement therapy for Gaucher disease. Beyond her leadership at NGF, she directs the Foundation's Global Diagnostic and Treatment Initiative, bringing diagnostic capabilities and treatment access to underserved regions worldwide. Additionally, her clinical research on the management of Gaucher disease is internationally recognized. Dr. Ely earned an M.D. from the Georgetown University School of Medicine.","length":604,"tagName":"p"},{"type":"text","content":"“We invited Dr. Ely to join our Advisory Board because her clinical experience and patient advocacy background align directly with Sharp’s efforts in orphan diseases, especially Gaucher disease,” said Scott Sneddon, Ph.D., J.D., Chief Executive Officer of Sharp Therapeutics. “Our mission is to develop medicines that restore function and meaningfully improve the lives of patients with genetic diseases. With ‘901 for Gaucher disease and a growing pipeline of programs in other high-need genetically defined indications, we aim to deliver transformative therapies for patients. As we prepare to initiate clinical studies later this year, Dr. Ely will bring unparalleled insights to our upcoming Phase 1 study and our anticipated ...